Top Tweets for #PostMenopausal
#Androgenexcess in #postmenopausal #women presents a #challenging clinical conundrum.
A crucial component in management involves #identification of underlying #etiology with detection of potential #malignantpathology or underlying #geneticsyndromes.
https://t.co/VYpLWSeKIA
Among #postmenopausal women with #hormone receptor-positive #DCIS treated with lumpectomy, whole-breast irradiation, and endocrine therapy, ipsilateral recurrence rates were low and similar across #surgical margin widths <1 mm, <2 mm, or wider.
https://t.co/WNRTjhddIw
🌸Recommended paper
Beetroot Supplementation as a Nutritional Strategy to Support Post-Exercise Autonomic Recovery in #Postmenopausal Women: A Systematic Review and Meta-Analysis
🖋️ by Rodrigo D. Raimundo et al.
https://t.co/DexKW8l5RN
In light of @US_FDA warnings about #AE of #statintherapy, some of #menopausalcomplaints, this study compared #menopause symptons #MenopauseRatingScale #MRS, #cognitive, and #musculoskeletal symptoms between users/non of #statins #postmenopausal #women.
https://t.co/KhusNpbRKV
Read the original article:
3 months vs 12 months of #romosozumab for #postmenopausal #osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial https://t.co/81eo7922l5
#OpenAccess
In the July Issue:
Benjamin Z Leder & colleagues reply to McClung et al:
Treatment duration for #romosozumab – Authors' reply https://t.co/WKUAsQz7v0
#postmenopausal #osteoporosis
#FREE to read
In the July Issue:
Michael R McClung & colleagues correspond on:
Treatment duration for #romosozumab https://t.co/RLHmqqSZjt
#postmenopausal #osteoporosis
#FREE to read
We examine the ambivalent biopolitics of media framing, where older women’s bodies are cast as both a ‘fertile’ promise and asexuality at once. #postmenopausal #motherhood #IVF #technology
https://t.co/vPlW9EA0Et
There is still time to comment on AHRQ’s draft #evidence report on "Improving the Management of #Menopausal Symptoms in #Perimenopausal and Early #Postmenopausal #Women," which has been posted on the @AHRQGov website at https://t.co/lBNIurDka4
The #vagina, vulva,#bladdertrigone have a high concentrtion of #estrogenreceptors; therefore, they are a sensitive biological indicator of levels of #hormones in #women. The #estrogenloss in #postmenopausal produces a #genitourinarysyndrome of #menopause.
https://t.co/paVFTnJRp6
#Postmenopausal #atherosclerosis is more than cholesterol only. New #JCTR review (ovariectomized mouse models)shows estrogen loss triggers a network of inflammation, oxidative stress, and lipid dysfunction👉https://t.co/uiFYHrtdme #cardiotwitter #ISCTR @ELaraPezzi @SpringerNature
Check out today's #ArticleinPress on menopause: Transcriptional Remodeling of Human #Skeletal #Muscle Following Sleep Restriction in #Postmenopausal Women (Hari Naga Sai Kiran Suryadevara et al. @PBRCNews):
https://t.co/41HpsfJjTl
Research Article by G Da Silva Rodrigues et al. (@j0nasbenjamim @fmrpusp @idac_tohoku_uni) #Epigenetic signatures and #geneticvariants associated with #muscle #strength in #postmenopausal women: potential #bone muscle cross talk via #BMP1 mechanisms
https://t.co/fN0xX6a84k
Sundeep Khosla comments on:
3 months of #romosozumab: a pragmatic clinical solution https://t.co/kos0Q7VyEv
#postmenopausal #osteoporosis
#FREE to read with registration (also FREE)
In the March Issue:
3 months vs 12 months of #romosozumab for #postmenopausal #osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial https://t.co/81eo7922l5
#OpenAccess
Treating peri- and #postmenopausal skin involves more than just chasing wrinkles. Bianca Viscomi, MD, recently explained how #hypoestrogenism affects the skin structure and collagen levels during a symposium at @imcascongress. https://t.co/oQ26VvalqN
Online—3 months vs 12 months of #romosozumab for #postmenopausal #osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial https://t.co/81eo7922l5
#BoneHealth #WomensHealth
#OpenAccess
In #postmenopausal #women at high risk of #fracture, 3 months of #romosozumab followed by 9 months of denosumab was non-inferior to 12 months of romosozumab in increasing total hip #BMD https://t.co/81eo7922l5
#osteoporosis #BoneHealth #WomensHealth
#OpenAccess
Sundeep Khosla comments on:
3 months of #romosozumab: a pragmatic clinical solution https://t.co/kos0Q7VyEv
#postmenopausal #osteoporosis #BoneHealth #WomensHealth
New—3 months vs 12 months of #romosozumab for #postmenopausal #osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial https://t.co/81eo7922l5
#BoneHealth #WomensHealth
#OpenAccess
Most Popular Users
Elon Musk 
@elonmusk
240.7M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.7M followers
Cristiano Ronaldo
@cristiano
110.9M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.7M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91M followers
KATY PERRY
@katyperry
87.8M followers
Taylor Swift
@taylorswift13
81.7M followers
Lady Gaga
@ladygaga
73.2M followers
Virat Kohli
@imvkohli
70.2M followers
Kim Kardashian
@kimkardashian
69.9M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64M followers
Neymar Jr
@neymarjr
63M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
Selena Gomez
@selenagomez
60.9M followers
X
@x
60.8M followers